When the price to buy insulin becomes prohibitive, the consequences are immediate and lethal. Because the demand for insulin is perfectly inelastic—meaning patients must have it regardless of price—consumers cannot simply choose to buy less of it when prices rise without facing severe health consequences. Faced with impossible choices, many patients are forced to engage in "insulin rationing," intentionally taking less than their prescribed dose to make their supply last longer.
The ethical crisis of buying insulin is rooted in a direct betrayal of its creators' intentions. In 1921, Frederick Banting, Charles Best, and James Collip discovered insulin at the University of Toronto. Recognizing the drug's absolute necessity for life, the discoverers famously sold the patent to the university for a symbolic one dollar each. Banting declared, "Insulin does not belong to me, it belongs to the world." They wanted to ensure that no person would ever die because they could not afford the medication. buy insulin
A century later, that humanitarian vision has been largely compromised by modern pharmaceutical economics. In the United States, the market is dominated by a powerful triad of manufacturers who have historically controlled about 90% of the supply. Through incremental patent extensions and slight formula tweaks—a process known as patent "evergreening"—these corporations have successfully blocked cheaper generic or biosimilar alternatives from flooding the market. Consequently, a drug that costs a few dollars to manufacture has historically carried list prices exceeding several hundred dollars per vial in the U.S., turning a basic human right into a luxury commodity. The Devastating Human Cost When the price to buy insulin becomes prohibitive,